Kintara Therapeutics, Inc. – NASDAQ:KTRA
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Kintara Therapeutics stock price monthly change
+47.43%
month
Kintara Therapeutics stock price quarterly change
+101.81%
quarter
Kintara Therapeutics stock price yearly change
-91.57%
year
Kintara Therapeutics key metrics
Market Cap | 11.98M |
Enterprise value | N/A |
P/E | -0.25 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.72 |
PEG ratio | N/A |
EPS | -8.64 |
Revenue | N/A |
EBITDA | -14.14M |
Income | -13.99M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeKintara Therapeutics stock price history
Kintara Therapeutics stock forecast
Kintara Therapeutics financial statements
| Jun 2022 | 0 | -5.42M | |
|---|---|---|---|
| Mar 2023 | 0 | -3.22M | |
| Jun 2023 | 0 | -3.33M | |
| Mar 2024 | 0 | -2.01M |
| 2028 | 21.01M | -972K | -4.63% |
|---|
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2020 | 0% |
|---|---|
| 2021 | 0% |
| 2022 | 0% |
| 2023 | 0% |
| 2024 | 0.02% |
| Dec 2022 | 9917000 | 3.31M | 33.47% |
|---|---|---|---|
| Mar 2023 | 6740000 | 2.95M | 43.83% |
| Jun 2023 | 3979000 | 3.24M | 81.63% |
| Mar 2024 | 7446000 | 1.52M | 20.47% |
| Jun 2022 | -4.99M | 0 | 7.93M |
|---|---|---|---|
| Mar 2023 | -1.82M | 0 | -2K |
| Jun 2023 | -1.50M | 0 | -2K |
| Mar 2024 | -2.3M | 0 | 7.99M |
Kintara Therapeutics alternative data
| Aug 2023 | 3 |
|---|---|
| Sep 2023 | 3 |
| Oct 2023 | 2 |
| Nov 2023 | 2 |
| Dec 2023 | 2 |
| Jan 2024 | 2 |
| Feb 2024 | 2 |
| Mar 2024 | 2 |
| Apr 2024 | 2 |
| May 2024 | 2 |
| Jun 2024 | 2 |
| Jul 2024 | 2 |
Kintara Therapeutics other data
1.50%
-7.35%
of KTRA is owned by hedge funds
11.43K
-55.93K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2021 | 3000 | 0 |
| Dec 2021 | 78700 | 0 |
| Feb 2022 | 55000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | HOFFMAN ROBERT E. director, officer: President an.. | Common Stock | 55,000 | $0.47 | $25,795 | ||
Purchase | PRAILL ANTHONY SCOTT officer: Chief Financial Officer | Common Stock | 28,700 | $0.68 | $19,430 | ||
Purchase | ZARRABIAN SAIID director, officer: Head of Stra.. | Common Stock | 38,109 | $0.64 | $24,314 | ||
Purchase | ZARRABIAN SAIID director, officer: Head of Stra.. | Common Stock | 11,891 | $0.59 | $7,016 | ||
Purchase | JOHNSON LAURA L. director | Common Stock | 3,000 | $0.74 | $2,226 | ||
Purchase | MURPHY KEITH director | Common Stock | 181,010 | N/A | N/A | ||
Purchase | LIATOS JOHN director, officer: SVP, Busines.. | Common Stock | 196,750 | N/A | N/A | ||
Purchase | BELL JOHN K director | Common Stock | 70,000 | $0.34 | $23,730 | ||
Purchase | BELL JOHN K director | Common Stock | 18,129 | $0.81 | $14,684 | ||
Purchase | BELL JOHN K director | Common Stock | 1,871 | $0.81 | $1,516 |
| Insider | Compensation |
|---|---|
Mr. Saiid Zarrabian B.Sc., M.B.A., MBA (1953) Head of Strategic Partnerships & Director | $700,830 |
Mr. Scott Praill B.Sc., C.P.A., CA, CPA, BSc (1967) Chief Financial Officer & Sec. | $369,810 |
Mr. Robert E. Hoffman CPA, CPA (1966) Pres, Chief Executive Officer & Chairman | $95,000 |
-
When is Kintara Therapeutics's next earnings date?
Unfortunately, Kintara Therapeutics's (KTRA) next earnings date is currently unknown.
-
Does Kintara Therapeutics pay dividends?
No, Kintara Therapeutics does not pay dividends.
-
How much money does Kintara Therapeutics make?
Kintara Therapeutics has a market capitalization of 11.98M.
-
What is Kintara Therapeutics's stock symbol?
Kintara Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "KTRA".
-
What is Kintara Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Kintara Therapeutics?
Shares of Kintara Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Kintara Therapeutics's key executives?
Kintara Therapeutics's management team includes the following people:
- Mr. Saiid Zarrabian B.Sc., M.B.A., MBA Head of Strategic Partnerships & Director(age: 72, pay: $700,830)
- Mr. Scott Praill B.Sc., C.P.A., CA, CPA, BSc Chief Financial Officer & Sec.(age: 58, pay: $369,810)
- Mr. Robert E. Hoffman CPA, CPA Pres, Chief Executive Officer & Chairman(age: 59, pay: $95,000)
-
How many employees does Kintara Therapeutics have?
As Jul 2024, Kintara Therapeutics employs 2 workers.
-
When Kintara Therapeutics went public?
Kintara Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 22 Feb 2013.
-
What is Kintara Therapeutics's official website?
The official website for Kintara Therapeutics is kintara.com.
-
Where are Kintara Therapeutics's headquarters?
Kintara Therapeutics is headquartered at 12707 High Bluff Drive, San Diego, CA.
-
How can i contact Kintara Therapeutics?
Kintara Therapeutics's mailing address is 12707 High Bluff Drive, San Diego, CA and company can be reached via phone at 858 350 4364.
Kintara Therapeutics company profile:
Kintara Therapeutics, Inc.
kintara.comExchange:
NASDAQ
Full time employees:
1
Industry:
Biotechnology
Sector:
Healthcare
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
12707 High Bluff Drive
San Diego, CA 92130
San Diego, CA 92130
CIK: 0001498382
ISIN: US49720K2006
CUSIP: 49720K101
